CLS1 — McKesson Europe AG Income Statement
0.000.00%
Last trade - 00:00
HealthcareConservativeLarge Cap
- €4.96bn
- €4.69bn
- €9.26bn
2018 March 31st | R2019 March 31st | 2020 March 31st | R2021 March 31st | 2022 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 21,090 | 16,417 | 17,118 | 8,518 | 9,257 |
Cost of Revenue | |||||
Gross Profit | 2,126 | 1,851 | 1,878 | 753 | 799 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 21,375 | 16,414 | 17,126 | 8,505 | 9,303 |
Operating Profit | -285 | 2.7 | -8.6 | 12.5 | -46.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -304 | 1.9 | -29.5 | 21.1 | -35.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -299 | -42.4 | -66.1 | 6.2 | -49.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -299 | -59 | -249 | -10.7 | -872 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -299 | -59 | -249 | -10.7 | -872 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.114 | 0.06 | -0.03 | 0.262 | 0.076 |
Dividends per Share |